The single-dose monoclonal antibody, Enflonsia, is designed to protect infants for up to 5 months — covering an entire respiratory syncytial virus season.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/new-rsv-prevention-option-newborns-wins-eu-support-2025a1000p6u?src=rss
Author :
Publish date : 2025-09-22 14:46:00
Copyright for syndicated content belongs to the linked Source.